Jan 7 (Reuters) - Sana Biotechnology Inc SANA.O:
SANA BIOTECHNOLOGY ANNOUNCES POSITIVE CLINICAL RESULTS FROM TYPE 1 DIABETES STUDY OF ISLET CELL TRANSPLANTATION WITHOUT IMMUNOSUPPRESSION
SANA BIOTECHNOLOGY INC - STUDY IDENTIFIES NO SAFETY ISSUES, HIP-MODIFIED ISLET CELLS EVADE IMMUNE RESPONSES
SANA BIOTECHNOLOGY INC -MRI SHOWS SIGNALS CONSISTENT WITH GRAFT SURVIVAL 28 DAYS AFTER TRANSPLANTATION
Source text: ID:nGNX996qx5
Further company coverage: SANA.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.